Defects in coagulation factors leading to recurrent pregnancy loss

Recurrent Pregnancy Loss: Causes, Controversies and Treatment

Volumn , Issue , 2007, Pages 127-290

  Carp, Howard J A ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80055055707     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (74)

1. Lorand L, Losowsky MS, Miloszewski KJ. Human factor XIII fibrin stabilizing factor. Progr Thromb Haemost 1980; 5:245–90.
2. Muszbek L, Adany R, Mikkola H. Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, and function. Crit Rev Clin Lab Sci 1996; 33:357–421.
3. Schubring C, Grulich-Henn J, Burkhard PAT, et al. Fibrinolysis and factor XIII in women with spontaneous abortion. Eur J Obstet Gynecol Reprod Biol 1990; 35:215–21.
4. Burrows RF, Ray JG, Burrows EA. Bleeding risk and reproductive capacity among patients with factor XIII deficiency: a case presentation and review of the literature. Obstet Gynecol Surv 2000; 55:103–7.
5. Mosher DF, Schad PE, Kleinman HK. Cross-linking of fibronectin to collagen by blood coagulation factor XIII. J Clin Invest 1979; 64:781–7.
6. Wartiovaara J, Leivo I, Virtanen I, et al. Cell surface and extracellular matrix glycoprotein fibronectin. Expression in embryogenesis and in teratocarcinoma differentiation. Ann NY Acad Sci 1978; 312:132–41.
7. Koseki-Kuno S, Yamakawa M, Dickneite G, et al. Factor XIII A subunit deficient mice developed severe uterine bleeding events and subsequent spontaneous miscarriages. Blood 2003; 102:4410–12.
8. Kobayashi T, Asahina T, Okada Y, et al. Studies on the localization of adhesive proteins associated with the development of extravillous cytotrophoblast. Trophoblast Res 1999; 13:35–53.
9. Asahina T, Kobayashi T, Okada Y, et al. Maternal blood coagulation factor XIII is associated with the development of cytotrophoblastic shell. Placenta 2000; 21:388–93.
10. Dardik R, Loscalzo J, Inbal A. Factor XIII (FXIII) and angiogenesis. J Thromb Haemost 2005; 4:19–25.
11. Anwar T, Miloszewski K. Factor XIII deficiency. Br J Haematol 1999; 107:468–84.
12. Reynolds TC, Butine MD, Visich JE, et al. Safety, pharmacokinetics, and immunogenicity of single-dose rFXIII administration J Thromb Haemost 2005; 3:922–8.
13. Hayano Y, Ima N, Kasaraura T. Studies on the physiologic changes of blood coagulation factor XIII during pregnancy and their significance. Acta Obstet Gynaecol Jpn 1982; 34:469–77.
14. Stirling Y, Woolf L, North WRS, et al. Haemostasis in normal pregnancy. Thromb Haemost 1984; 52:176.
15. Ogasawara MS, Aoki K, Katano K, et al. Factor XII but not protein C, protein S, antithrombin III, or factor XIII is a predictor of recurrent miscarriage. Fertil Steril 2001; 75:916–19.
16. Anwar R, Gallivan L, Edmonds SD, et al. Genotype/phenotype correlations for coagulation factor XIII: specific normal polymorphisms are associated with high or low factor XIII specific activity. Blood 1999; 93:897–905.
17. Galanakis DK. Fibrinogen anomalies and disease. A clinical update. Hematol Oncol Clin North Am 1992; 6:1171–87.
18. Doolittle RF. The molecular biology of fibrin. In: Stamatoyannopoulos GS, Nienhuis AW, Majerus PW, Harmus H, eds. The Molecular Basis of Blood Diseases. Philadelphia: WB Saunders, 1994:701–23.
19. Brenner B. Inherited thrombophilia and fetal loss. Curr Opin Hematol 2000; 7:290–5.
20. Mosesson MW. Dysfibrinogenemia and thrombosis. Semin Thromb Hemost 1999; 25:311–19.
21. Ridgway HJ, Brennan SO, Faed JM, et al. Fibrinogen Otago: a major a chain truncation associated with severe hypofibrinogenaemia and recurrent miscarriage. Br J Haematol 1997; 98:632–9.
22. Suh TT, Holmback K, Jensen N, et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 1995; 9:2020–33.
23. Inamoto Y, Terao T. First report of a case of congenital afibrinogenemia with successful delivery. Am J Obstet Gynecol 1985; 153:803–4.
24. Gilabert J, Reganon E, Vila V, et al. Congenital hypofibrinogenemia and pregnancy: obstetric and hematological management. Gynecol Obstet Invest 1987; 24:271–6.
25. MacKinnon HH, Fekete JF. Congenital afibrinogenemia: vascular changes and multiple thromboses induced by fibrinogen infusions and contraceptive medication. CMAJ 1971; 140:597–9.
26. Beck EA. Congenital abnormalities of fibrinogen. Clin Haematol 1979; 8:169–81.
27. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344:1222–31.
28. Many A, Schreiber L, Rosner S, et al. Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia. Obstet Gynecol 2001; 98:1041–4.
29. Rushton DI. Simplified classification of spontaneous abortions. J Med Genet 1978; 15:1–9.
30. Mousa HA, Alfirevic Z. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome? Hum Reprod 2000; 15:1830–3.
31. Arias F, Romero R, Joist H, et al. Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in the placenta. J Matern Fetal Med 1998; 7:277–86.
32. Lyden TW, Vogt E, Ng AK, et al. Monoclonal antiphospholipid antibody reactivity against human placental trophoblast. J Reprod Immunol 1992;22:1–14.
33. Sood R, Kalloway S, Mast AE, et al. Fetomaternal cross talk in the placental vascular bed: control of coagulation by trophoblast cells. Blood 2006; 107:3173–80.
34. Kupferminc MJ. Thrombophilia and pregnancy. Reprod Biol Endocrinol 2003; 1:111.
35. Brenner B, Sarig G, Weiner Z, et al. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Haemost 1999; 82:6–9.
36. Rey E, Kahn SR, David M, et al. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361:901–8.
37. Krabbendam I, Franx A, Bots ML, et al. Thrombophilias and recurrent pregnancy loss: a critical appraisal of the literature. Eur J Obstet Gynecol Reprod Biol 2005; 118:143–53.
38. Nelen WL, Blom HJ, Steegers EA, et al. Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis. Fertil Steril 2000; 74:1196–9.
39. Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348:913–16.
40. Sarig G, Younis JS, Hoffman R, et al. Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage. Fertil Steril 2002; 77:342–7.
41. Grandone E, Margaglione M, Colaizzo D, et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost 1997; 77:822–4.
42. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilias in women with complications of pregnancy. N Engl J Med 1999; 340:9–13.
43. Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol 2002; 101:6–14.
44. Gris JC, Quere I, Monpeyroux F, et al. Case-control study of the frequency of thrombophilic disorders in couples with late fetal loss and no thrombotic antecedent. The Nimes Obstetricians and Haematologists Study (NOHA). Thromb Haemost 1999; 81:891–9.
45. Many A, Elad R, Yaron Y, et al. Third-trimester unexplained intrauterine fetal death is associated with inherited thrombophilia. Obstet Gynecol 2002; 99:684–7.
46. Infante-Rivard C, Rivard GE, Yotov WV, et al. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N Engl J Med 2002; 347:19–25.
47. Carp HJA, Dolitzky M, Inbal A. Hereditary thrombophilias are not associated with a decreased live birth rate in women with recurrent miscarriage. Fertil Steril 2002; 78:58–62.
48. Salomon O, Seligsohn U, Steinberg DM, et al. The common pro- thrombotic factors in nulliparous women do not compromise blood flow in the feto-maternal circulation and are not associated with preeclampsia or intrauterine growth restriction. Am J Obstet Gynecol 2004; 191:2002–9.
49. Lindqvist PG, Svensson PJ, Marsâ K, et al. Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost 1999; 81:532–7.
50. Sanson BJ, Friederich PW, Simioni P, et al. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost 1996; 75:387–8.
51. Gris JC, Mercier E, Quere I, et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103:3695–9.
52. Carp HJA, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Hemost 2003; 1:433–8.
53. Brenner B, Hoffman R, Carp HJA, et al. The LIVE-ENOX Investigators. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost 2005; 3:227–9.
54. Lantz M, Thysell H, Nilsson E, et al. On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-bind- ing protein I by heparin. J Clin Invest 1991; 88:2026–31.
55. Baram D, Rashkovsky M, Hershkoviz R, et al. Inhibitory effects of low molecular weight heparin on mediator release by mast cells: preferential inhibition of cytokine production and mast cell-dependent cutaneous inflammation. Clin Exp Immunol 1997; 110:485–91.
56. Downing LJ, Strieter RM, Kadell AM, et al. Low-dose low-molecular- weight heparin is anti-inflammatory during venous thrombosis. J Vasc Surg 1998; 28:848–54.
57. Bose P, Black S, Kadyrov M, et al. Adverse effects of lupus anticoagulant positive blood sera on placental viability can be prevented by heparin in vitro. Am J Obstet Gynecol 2004; 191:2125–31.
58. Carp HJA, Torchinsky A, Fein A, et al. Hormones, cytokines and fetal anomalies in habitual abortion. J Gynecol Endocrinol 2002; 15:472–83.
59. Krause I, Blank M, Levi Y, et al. Anti-idiotype mmunomodulation of experimental antiphospholipid syndrome via effect on Th1/Th2 expression. Clin Exp Immunol 1999; 117:190–7.
60. Darmochwal-Kolarz D, Rolinski J, Leszczynska-Goarzelak B, et al. The expressions of intracellular cytokines in the lymphocytes of preeclamptic patients. Am J Reprod Immunol 2002; 48:381–6.
61. Maymon E, Ghezzi F, Edwin SS, et al. The tumor necrosis factor alpha and its soluble receptor profile in term and preterm parturition. Am J Obstet Gynecol 1999; 181:1142–8.
62. Hahn-Zoric M, Hagberg H, Kjellmer I, et al. Aberrations in placental cytokine mRNA related to intrauterine growth retardation. Pediatr Res 2002;51:201–6.
63. Brill A, Torchinsky A., Carp HJA, et al. The role ofapoptosis in normal and abnormal embryonic development. J Assist Reprod Genet 1999; 16:512–19.
64. Laude I, Rongieres-Bertrand C, Boyer-Neumann C, et al. Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight. Thromb Haemost 2001; 85:18–21.
65. Carp HJA, Dardik R, Lubetsky A, et al. Prevalence of circulating procoagulant microparticles in women with recurrent miscarriage: a case controlled study. Hum Reprod 2004; 19:191–5.
66. Meilahn EN, Kuller LH, Matthews KA, et al. Hemostatic factors according to menopausal status and use of hormone replacement therapy. Ann Epidemiol 1992; 2:445–55.
67. Cosman F, Baz-Hecht M, Cushman M, et al. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized- controlled study and review of the literature. Thromb Res 2005; 116:1–13.
68. Tong MH, Jiang H, Liu P, et al. Spontaneous fetal loss caused by placental thrombosis in estrogen sulfotransferase-deficient mice. Nat Med 2005; 11:153–9.
69. Polan ML, Daniele A, Kuo A. Gonadal steroids modulate human monocyte interleukin-1 (IL-1) activity. Fertil Steril 1988; 49:964–8.
70. Schatz F, Krikun G, Caze R, et al. Progestin-regulated expression of tissue factor in decidual cells: implications in endometrial hemostasis, menstruation and angiogenesis. Steroids 2003; 68:849–60.
71. Smiley ST, Boyer SN, Heeb MJ, et al. Protein S is inducible by interleukin 4 in T cells and inhibits lymphoid cell procoagulant activity. Proc Natl Acad Sci USA 1997; 94:11484–9.
72. Raghupathy R, Al Mutawa E, Makhseed M, et al. Modulation of cytokine prouction by dydrogesterone in lymphocytes from women with recurrent miscarriage. Br J Obset Gynaecol 2005; 112:1096–101.
73. Uzumcu M, Coskun S, Jaroudi K, et al. Effect of human chorionic gonadotropin on cytokine production from human endometrial cells in vitro. Am J Reprod Immunol 1998; 40:83–8.
74. Rosing J. Mechanisms of OC related thrombosis. Thromb Res 2005; 115(Suppl 1):81–3.